Novartis AG (NVS) Q2 2012 Earnings Call July 19, 2012 8:00 am ET Executives Joseph Jimenez - Chief Executive Officer Susanne Schaffert - Head of Oncology - Novartis Pharma Germany Jonathan Symonds - Chief Financial Officer David Epstein - Division Head of Novartis Pharmaceuticals Brian Mcnamara - Division Head of Novartis Otc Kevin J. Buehler - President, Chief Executive Officer, and Chairman Andrin Oswald - Division Head of Vaccines & Diagnostics Jeffrey George - Division Head of Sandoz and Member of Executive Committee Analysts Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division Alistair D. Campbell - Berenberg Bank, Research Division Alexandra Hauber - JP Morgan Chase & Co, Research Division Matthew Weston - Crédit Suisse AG, Research Division Naresh Chouhan - Liberum Capital Limited, Research Division Michael Leuchten - Barclays Capital, Research Division Andrew C. Weiss - Bank Vontobel AG, Research Division Seamus Fernandez - Leerink Swann LLC, Research Division Florent Cespedes - Exane BNP Paribas, Research Division Andrew S. Baum - Citigroup Inc, Research Division Peter Verdult - Morgan Stanley, Research Division Florian Gaiser PresentationOperator
Good morning and good afternoon, and welcome to the Novartis Q2 Half Year 2012 Results Conference Call and Live Webcast. [Operator Instructions] The conference is being recorded. [Operator Instructions] With that, I would like to hand over to Mr. Joe Jimenez, CEO of Novartis. Please go ahead, sir. Joseph Jimenez Thank you. I'd like to welcome everyone to our second quarter and first-half conference call. With me today on the Novartis end are Jon Symonds, the CFO; David Epstein, Head of Pharma; we have all of the division heads, and we have Tim Wright, who is the Head of Pharma Development, with us. So before we begin, I'd like to ask Susanne Schaffert to read the Safe Harbor statement.